Stanford researchers identify BRP molecule as potential weight-loss treatment with fewer side effects
Updated
Updated · DW (English) · Apr 24
Stanford researchers identify BRP molecule as potential weight-loss treatment with fewer side effects
6 articles · Updated · DW (English) · Apr 24
The 12-amino-acid BRP molecule, discovered using an AI tool at Stanford Medicine, helped obese mice lose fat without muscle loss and caused fewer side effects compared to GLP-1 drugs.
BRP acts mainly on the hypothalamus, potentially reducing nausea and other common issues seen with current weight-loss injections like Ozempic and Wegovy. Human clinical trials are planned by a company co-founded by the study's senior author.
Experts caution that animal trial results may not translate directly to humans, but BRP could become a valuable alternative as obesity rates rise globally. Existing GLP-1 drugs will likely remain important for their broader health benefits.
With 'Triple G' drugs showing 24% weight loss, can BRP’s better side-effect profile truly compete?
How does BRP's muscle-sparing effect work, and can this mechanism be applied to other conditions?
If BRP eliminates side effects, will society become over-reliant on a pill for weight control?
The AI found BRP. What other game-changing molecules are hiding in its other 2,682 predictions?
What unforeseen risks come from a drug that so precisely targets the brain's central hunger switch?
From AI Discovery to Human Trials: The Promise and Challenges of the BRP Peptide for Obesity (2026–2031)
Overview
In March 2025, Dr. Katrin Svensson and her team discovered the BRP peptide using AI, revealing its ability to suppress appetite and promote weight loss in animals through a unique hypothalamic pathway. Unlike current drugs like semaglutide, BRP causes fat loss without common side effects such as nausea or muscle loss. Following this breakthrough, Dr. Svensson co-founded a company to advance BRP, which remains in preclinical development as of April 2026. Phase I human trials are planned for 2026-2027 to assess safety and tolerability. Experts are excited about BRP's potential, especially its distinct mechanism that may allow combination therapies and improved treatment options for obesity.